Diagnostic Value of Methylated Septin9 for Colorectal Cancer Screening: A Meta-Analysis.
BACKGROUND Septin9 is a member of GTP-binding protein family, and is used as a predictive diagnostic index. However, it has not been widely adopted due to inconsistent results reported in the literature. The present study was performed to determine the diagnostic accuracy of methylated Septin9 (mSEPT9) for colorectal cancer (CRC) and to evaluate its utility in CRC screening. MATERIAL AND METHODS After reviewing relevant studies, accuracy measures (pooled sensitivity and specificity, positive/negative likelihood ratio [PLR/NLR], and diagnostic odds ratio [DOR]) were calculated for mSEPT9 in the diagnosis of CRC. Overall test performance was summarized using summary receiver operating characteristic curve analysis. Potential between-study heterogeneity was explored by use of a meta-regression model. We divided included studies into Epi proColon test and non-Epi proColon test subgroups. We compared the effects of mSEPT9 and fecal occult blood test (FOBT) for CRC screening. RESULTS A total of 9870 subjects in 14 studies were recruited. Pooled sensitivity and specificity, PLR, NLR, DOR, and corresponding 95% confidence intervals (CI) of mSEPT9 for CRC diagnosis were 0.66 (95% CI: 0.64-0.69), 0.91 (95% CI: 0.90-0.91), 5.59 (95% CI: 4.03-7.74), 0.37 (95% CI: 0.29-0.48), and 16.79 (95% CI: 10.54-26.76), respectively. The area under the summary ROC curve (AUC) was 0.8563. The AUCs in the Epi proColon test and non-Epi proColon test for CRC diagnosis were 0.8709 and 0.7968, respectively. In head-to-head comparison, AUC of mSEPT9 and FOBT for CRC diagnosis were 0.7857 and 0.6571, respectively. CONCLUSIONS The present study demonstrates that mSEPT9 can be a good diagnostic biomarker complementary to FOBT as a screening tool for CRC.
Department of Clinical Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland).
Shirong
S
Yan
Department of Clinical Medicine, Xinjiang Medical University, Urumqi, Xinjiang, China (mainland).
Zijing
Z
Liu
Department of Clinical Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland).
Shuang
S
Yu
Department of Clinical Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland).
Yixi
Y
Bao
Ann Intern Med. 2012 Mar 6;156(5):378-86
22393133
PLoS One. 2015 May 06;10(5):e0126417
25946211
Am J Gastroenterol. 2008 Jun;103(6):1541-9
18479499
Epigenetics Chromatin. 2010 Jun 02;3(1):12
20525169
BMC Cancer. 2014 Jan 31;14:54
24485021
Pathol Oncol Res. 2011 Sep;17(3):503-9
21267688
J Clin Epidemiol. 2003 Nov;56(11):1129-35
14615004
Ann Intern Med. 2009 Jan 6;150(1):1-8
19075198
Stat Med. 1993 Jul 30;12 (14 ):1293-316
8210827
BMC Med. 2011 Dec 14;9:133
22168215
Ann Intern Med. 2011 Oct 18;155(8):529-36
22007046
Clin Chem. 2008 Feb;54(2):414-23
18089654
Cancer Genet Cytogenet. 2010 Oct 1;202(1):1-10
20804913
J Gastroenterol Hepatol. 2015 May;30(5):830-3
25471329
Clin Chem. 2005 Aug;51(8):1335-41
15961549
Clin Chem. 2009 Jul;55(7):1337-46
19406918
Int J Cancer. 2011 Jan 1;128(1):3-11
20824704
Clin Endosc. 2012 Mar;45(1):25-43
22741131
Psychol Methods. 2006 Jun;11(2):193-206
16784338
Cancer Prev Res (Phila). 2012 Feb;5(2):336-42
22166248
BMC Cancer. 2011 Sep 25;11(1):408
21942990
Gastroenterology. 2008 May;134(5):1570-95
18384785
PLoS One. 2008;3(11):e3759
19018278
Clin Cancer Res. 2011 Mar 15;17(6):1535-45
21278247
PLoS One. 2010 Feb 04;5(2):e9061
20140221
JAMA. 1994 Mar 2;271(9):703-7
8309035
CA Cancer J Clin. 2009 Nov-Dec;59(6):366-78
19897840
Clin Gastroenterol Hepatol. 2012 Mar;10(3):272-7.e1
22019796
PLoS One. 2012;7(9):e46000
23049919
Stat Med. 2002 May 15;21(9):1237-56
12111876
Transl Oncol. 2013 Jun 01;6(3):290-6
23730408
Endosc Int Open. 2014 Jun;2(2):E96-E104
26135268
J Pathol. 2004 Nov;204(4):489-505
15495264
PLoS One. 2014 Jun 05;9(6):e98238
24901436
PLoS One. 2014 Dec 19;9(12):e115415
25526039
Am J Gastroenterol. 2011 Jun;106(6):1110-8
21326223
J Gen Intern Med. 2010 Nov;25(11):1211-21
20499198
Surg Oncol. 2009 Mar;18(1):15-24
18619834
Cancer. 2014 Oct 15;120(20):3131-41
24925595
Biomarkers. 2013 Aug;18(5):399-405
23862763
Gut. 2014 Feb;63(2):317-25
23408352
Ann Intern Med. 2005 Jan 18;142(2):81-5
15657155
Ann Thorac Surg. 2005 Jan;79(1):16-20
15620907
J Cancer Res Clin Oncol. 2016 Feb;142(2):341-51
25687380
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
21685461
J Clin Oncol. 2006 Nov 20;24(33):5313-27
17060676
Clin Chem. 2014 Sep;60(9):1183-91
24938752
J Clin Epidemiol. 2005 Oct;58(10):982-90
16168343
Cancer Causes Control. 2005 Mar;16(2):171-88
15868457
BMC Cancer. 2012 Sep 07;12:393
22954206
Future Oncol. 2013 Jul;9(7):1017-27
23837764